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Inﬂammatory mechanisms play a key role in the pathogenesis of type 1 and type 2 diabetes. IL6, a
pleiotropic cytokine with impact on immune and non-immune cell types, has been proposed to be
involved in the events causing both forms of diabetes and to play a key role in experimental insulin-
dependent diabetes development. The aim of this study was to investigate how beta-cell speciﬁc over-
expression of IL-6 inﬂuences diabetes development. We developed two lines of rat insulin promoter
(RIP)-lymphocytic choriomeningitis virus (LCMV) mice that also co-express IL6 in their beta-cells.
Expression of the viral nucleoprotein (NP), which has a predominantly intracellular localization,
together with IL6 led to hyperglycemia, which was associated with a loss of GLUT-2 expression in
the pancreatic beta-cells and inﬁltration of CD11bþ cells, but not T cells, in the pancreas. In contrast,
overexpression of the LCMV glycoprotein (GP), which can localize to the surface, with IL-6 did not lead to
spontaneous diabetes, but accelerated virus-induced diabetes by increasing autoantigen-speciﬁc CD8þ T
cell responses and reducing the regulatory T cell fraction, leading to increased pancreatic inﬁltration by
CD4þ and CD8þ T cells as well as CD11bþ and CD11cþ cells. The production of IL-6 in beta-cells acts
prodiabetic, underscoring the potential beneﬁt of targeting IL6 in diabetes.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Diabetes mellitus is a chronic metabolic disorder that is caused
by a failure of the body to produce insulin (type 1 diabetes, T1D)
and/or the inability of the body to respond adequately to circulating
insulin (type 2 diabetes, T2D). While type 1 and type 2 diabetesin-dependent diabetes melli-
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Ltd. This is an open access article uhave different etiology and pathogenesis, both types of diabetes
share inﬂammation as a common trait. About 5e10% of diabetic
patients suffer from T1D, the most common metabolic disease in
childhood and adolescence affecting 112,000 children younger than
16 in Europe [1]. In recent years, prevalence has not only risen, but
T1D became increasingly diagnosed at younger ages [2]. In type 1 or
insulin-dependent diabetes mellitus (IDDM), the pancreatic islets
and, speciﬁcally, the islet beta-cells become the target of an auto-
immune response which destroys their insulin-producing capacity
[3]. Human enterovirus (HEV) infections have long been suspected
as environmental triggers of human T1D [4]. Cytokines have been
implicated in the development of the characteristic islet mono-
nuclear cell inﬁltrate (termed insulitis) and may also mediate cell
toxicity in IDDM [5].
Interleukin (IL)6 is a pleiotropic cytokine with a key impact on
both immunoregulation and non-immune events in most cell types
and tissues outside the immune system [6,7], including but not
limited to ﬁbroblasts, endothelial cells, keratinocytes, monocytes/
macrophages, T cell lines, mast cells, and a variety of tumor cell
lines [8]. A vast number of epidemiological, genetic, rodent, andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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pathogenic actions of IL6 in diabetes, both type 1 and type 2 [6].
In human T2D, concentrations of IL6 in the serum are not only
predictive of the disease development but are also increased in T2D
patients [9,10]. T1D patients also have higher concentrations of IL6
in the serum as well as in the artery wall, compared with non-
diabetic subjects [11,12]. Studies in experimental models further
show that IL6 is produced by isolatedmouse islets after exposure to
interferon-g (IFN-g) and tumor necrosis factor-a (TNF-a) [13]. IL6 is
also present in inﬁltrated islets before and during immune inﬁl-
tration in non-obese diabetes (NOD) mice, a model for type 1 dia-
betes. The observation of higher IL6 expression in the islets of NOD
females than in those of males supports a deleterious effect of IL6
[14,15]. Indeed, beta-cell-speciﬁc overexpression of IL6 promotes
islet inﬂammation in NOD mice [16] and in a non-diabetes-prone
mouse strain [17] and IL6 is essential for diabetes development in
the NOD [18].
Adoptively transferred self-reactive, activated CTL home to the
islets and surround the islets of RIP-LCMV transgenic (Tg) mice, but
require additional factors, such as upregulation of MHC class II
molecules and activation of antigen-presenting cells, to enter the
islets (insulitis) and cause hyperglycemia [19]. We tested here the
impact of local production of IL6 as additional factor on diabetes
development in virus-induced diabetes. Conversely, the observa-
tion by Campbell et al. that IL6 expression causes insulitis, but not
diabetes, in IL6 Tgmice [17] led us to test whether additional factors
such as viral infection and/or co-expression of neo-autoantigens
are required to trigger diabetes in IL6 Tg mice.
2. Research design and methods
2.1. Mice, infections and diabetes incidence
Mice expressing murine IL6 under the rat insulin promoter
(RIP), RIP-IL6, were generated before [17]. RIP-IL6 mice were
crossed to RIP-LCMV-nucleoprotein (NP) and RIP-LCMV-
glycoprotein (GP) (C57Bl/6 background) to generate RIP-NP/IL6
and RIP-GP/IL6, respectively. Where indicated, mice were inocu-
lated with LCMV Armstrong 53b (104 pfu i.p. for diabetes induction
in RIP-LCMV, or 106 pfu i.p. for RIP-IL6 in Fig. 6), with Coxsackie
Virus B3/GA (CVB3/GA, slower replicator, 5  106 TCID50 i.p.), or
with Coxsackie Virus B3/28 (CVB3/28, fast replicator, 5105 TCID50
i.p.). For spontaneous diabetes, mice were monitored weekly and
mice were considered diabetes on the ﬁrst of 2 consecutive blood
glucose readings above 250 mg/dl. Of note, the wild-type litter-
mates of these transgenic mouse strains had relatively high base-
line blood glucose concentrations: the ‘NP/IL6’ wildtypes had on
average 190 mg/dl (males) and 160 mg/dl (females), and the ‘GP/
IL6’ wildtypes had on average 175 mg/dl (males) and 160 mg/dl
(females). For LCMV-induced diabetes, mice were monitored daily
and were considered diabetes on the ﬁrst of 2 consecutive blood
glucose readings above 250 mg/dl.
2.2. Immunohistochemistry
Pancreata were harvested and snap-frozen in OCT Compound
(Tissue-Tek, Sakura Finetek USA, Torrance, CA). Six micron tissue
sections were ﬁxed in acetone (10 min RT) before rehydration
and biotin/avidin blocking, then incubated with biotinylated
anti-mouse CD8, CD4, CD45R/B220, or CD11b in TBS/2%FCS/2%GS
(all 1:50, BD Biosciences, San Jose, CA), and guinea pig anti-
swine insulin (1:500, Dako)(1 h RT). Next, sections were
washed before secondary incubation with goat anti-guinea pig
AP (1:50, Sigma) and avidin-HRP (1:2000, Vector Labs, Burlin-
game, CA) in TBS/2%FBS/2%GS. AP or HRP activity was visualizedusing Vector Blue AP III (Vector Labs, blue signal) or AEC sub-
strate (red precipitates), respectively. Slides were mounted (Dako
Faramount Aqueous Mounting Medium, Dako, Carpinteria, CA)
without hematoxylin counterstain. Original JPEG ﬁles were
adjusted in Photoshop: Image > Auto Tone, then contrast set to
50 and saved as TIFF.
2.3. Immunoﬂuorescence
Sections were prepared as for immunohistochemistry. For mu-
rine IL6 detection, sections were ﬁrst incubated in goat anti-mouse
IL6 (R&D Systems, Minneapolis, MN; 15 mg/ml in TBS/2%Rabbit
Serum (RS); 1 h at RT), washed and incubated with biotinylated
rabbit anti-goat (Vector Labs, 1:1000 in TBS/2%RS), washed and
incubated in streptavidin-AF488 (Invitrogen, Carlsbad, CA; 1:1000
in TBS/2%RS) (both 45 min at RT). Insulin or GLUT-2 was detected
on consecutive sections to circumvent crossreactivity. For insulin,
sections were incubated (all 1 h RT) in guinea pig anti-swine insulin
antibody (1:140 in TBS/2%GS), washed and incubated with goat
polyclonal anti-guinea pig AF488 (Invitrogen; 1:1000 in TBS/2%GS).
For GLUT-2 staining, sections were incubated in polyclonal rabbit
anti-GLUT-2 (Millipore, Temecula, CA; 1:400 in TBS/2%GS), washed
and incubated with goat polyclonal anti-rabbit AF594 antibody
(Invitrogen; 1:1000 in TBS/2%GS). Slides were mounted in Prolong
Gold anti-fade reagent. Pictures were RGB split to obtain the rele-
vant channel and background subtracted using ImageJ. For full
pancreas overview, pictures at 10 magniﬁcation were merged
using Photomerge in Adobe Photoshop.
2.4. Glucose tolerance tests (GTT)
Mice were fasted for 16 h and injected intraperitoneally with
glucose (2 g/kg). Blood glucose concentration was monitored as
indicated using OneTouch Ultra glucometer via tail vein blood
sampling (approximately 5 ml).
2.5. Insulin sensitivity test (IST)
Mice were fasted for 4 h and injected intraperitoneally with
insulin (Humalog, Eli Lilly, Indianapolis, IN; diluted in 0.9% saline;
0.75 units/kg). Blood glucose concentrationwasmeasured at 15, 30,
45 and 60 min after injection.
2.6. Flow cytometry
Fluorochrome-labeled mAbs were from BD Biosciences, eBio-
science (San Diego, CA), or BioLegend (San Diego, CA). After Fc block
(1 mg/ml; 10 min RT), cells were incubated with antibodies to CD3,
CD4, CD8a, CD19, CD25 and Foxp3 (20 min 6e8 C). Foxp3 staining
was performed using eBioscience reagents. LCMV/GP33-41/H-2Db
pentamer staining was done for 30 min at RT (10 ml/sample,
ProImmune). LCMV-GP-speciﬁc CD8 responses were measured af-
ter 5 h ex vivo restimulation with 1 mg/ml gp33-41 peptide and T
cell-depleted splenocytes (TdS, only for pLN) in the presence of
10 mg/ml Brefeldin A. TdS were prepared using pan T cell beads
(CD90.2, Invitrogen) and irradiated (3000 rad equivalent) using an
RS2000 X-ray irradiator (Rad Source, Suwanee, GA). After antigen-
speciﬁc stimulation, intracellular cytokines IFN-g and TNF-a were
detected after ﬁxation and permeabilization using BD Cytoﬁx/
CytoPerm reagents. Exclusion of dead cells was done using the Live
Dead dyes (Aqua or Violet, Invitrogen) for 20 min at RT, prior to
ﬁxation for ICCS or Foxp3 staining. Stained samples were acquired
on LSRII (BD Biosciences). Data were analyzed using FlowJo
(Treestar, Ashland, OR).
T.L. Van Belle et al. / Journal of Autoimmunity 55 (2014) 24e32262.7. Q-PCR analysis
Pancreas sections frommice were cut and RNAwas extracted by
placing samples in the RLT buffer and following instructions from
Qiagen’s RNEasy extraction kit. Two micrograms of RNA were
reverse-transcribed into complementary DNA (cDNA) using the
RNA-to-cDNA kit (Applied Biosystems) according to the manufac-
turer’s instructions. Five microliters of cDNA diluted 1/20 in
nuclease-freewater was used to run quantitative PCRs in duplicates
(total volume of 25 ml).
2.8. Statistical analysis
Graphs and statistical analysis were done using Prism 5.0
(GraphPad, La Jolla, CA). For diabetes incidence, signiﬁcance was
calculated by log-rank test (ManteleCox). For cell subset analysis,
non-parametric t-test ManneWhitney (two-tailed) was used. Sta-
tistical signiﬁcance is indicated as follows: *P < 0.05, **P < 0.01,
***P < 0.001.
2.9. Ethics
All the studies were performed in the La Jolla Institute for Al-
lergy and Immunology upon approval of LIAI’s Animal Care and Use
Committee.
3. Results
3.1. Co-expression of viral protein and IL6 can cause spontaneous
diabetes development
The presence of high numbers of activated autoreactive T cells
that recognize an islet self-antigen (e.g. a viral transgene) is not
always sufﬁcient for beta-cell destruction [19]. Induction of dia-
betes in RIP-LCMV mice by inoculation with LCMV causes a rapid
upregulation of MHCII and activation of macrophages in the islets
[19]. Because macrophages can produce IL6 [20] and IL6 is essential
for diabetes onset [18], we examined how beta-cell speciﬁc IL6
production impacts immune cell recruitment to the pancreas and
diabetes development.
We crossed RIP-IL6 Tg mice [17], expressing IL6 speciﬁcally in
the pancreatic beta-cells (Fig. 1A), to RIP-LCMV-GP or RIP-LCMV-NP
C57Bl/6, expressing glycoprotein (GP) or nucleoprotein (NP) of
LCMV as a self-antigen in their pancreatic beta-cells and in some
lines, in the thymus [21]. Without LCMV inoculation, F1 offspringFig. 1. Simultaneous production of autoantigen and IL6 in the beta-cells causes diabetes. A: I
DAPI; dotted lines delineate pancreatic islets. Pancreatic islets shown are representative for a
female (right) RIP-NP/IL6 double Tg mice (B) and RIP-GP/IL6 double Tg mice (C), as indicated
IL6 gene expression in pancreas sections of RIP-NP/IL6 (top) and RIP-GP/IL6 (bottom) transge
**P < 0.01. Lines represent means.expressing either a neo-autoantigen or IL6 alone did not develop
diabetes (Fig. 1B and C) [17,21], indicating the produced levels of IL6
are not toxic to the beta-cells. Remarkably, simultaneous expres-
sion of both IL6 and the neo-autoantigen NP caused hyperglycemia
in all mice, even without LCMV inoculation (Fig. 1B). In male RIP-
NPþ/IL6þ double Tg mice, incidence of hyperglycemia started by
week 5 of age and afﬂicted all mice by week 9. In female RIP-NPþ/
IL6þ double Tg mice, hyperglycemia was observed starting week 6
and reaching 100% penetration by week 16. In contrast, simulta-
neous expression of IL6 and the neo-autoantigen GP did not raise
blood glycemia in female mice and only in 25% of themale RIP-GPþ/
IL6þ double Tg mice (Fig. 1C). We next tested whether the differ-
ences in the magnitude of expression of IL6 explained the very
different pattern of diabetes development displayed by RIP-GP and
RIP-NPmicewhen crossedwith RIP-IL6mice. This revealed that the
amounts of IL6 transcript in the pancreas did not differ between the
RIP-NP/IL6 and the RIP-GP/IL6 line (Fig. 1D), even though IL-6 Tg
mice contained clearly higher amounts of IL-6 transcripts in the
pancreas than IL-6 non-Tg mice.
3.2. CD11bþ cells, but not T cells, inﬁltrate the pancreas in RIP-NPþ/
IL6þ double Tg mice
Previous histological examination revealed that islets often
displayed irregular boundaries, numerous ducts surrounding the
islets and islet inﬂammation [17]. We conﬁrm this in RIP-NP/IL6þ
and RIP-NPþ/IL6þ mice (data not shown) and further determined
which immune cell types inﬁltrated the pancreas of hyperglycemic
RIP-NPþ/IL6þ mice. As expected, no CD11bþ, CD4þ or CD8þ T cells
were detectable in non-Tg littermates. In line with our previous
data on mice at older age [17], CD11bþ cells inﬁltrated the pancreas
in RIP-NP/IL6þ mice already at the age of 5 weeks (Fig. 2A).
However, CD4þ and CD8þ T cells were absent from immune in-
ﬁltrates in islets of RIP-NP/IL6þ mice. We then examined the im-
mune inﬁltrate in pancreata of RIP-NPþ/IL6þ double Tg mice at 5
weeks of age, i.e. prior to the development of hyperglycemia, and
found that co-expression of NP and IL6 increased the amount of
CD11bþ cells in the immune inﬁltrate, but did not cause inﬁltration
by T cells at this age.
To determinewhether the increased inﬂux of CD11b also reﬂects
a qualitative change in the nature of the CD11bþ cells, we assessed
if IL6 expression in the pancreas shifts the balance of macrophages
from anM2-phenotype to a more proinﬂammatory M1-phenotype.
We measured (in the pancreas) the expression inducible nitric
oxide synthase (Inos, pro-M1), arginase-1 (Arg1, pro-M2) as well asmmunoﬂuorescence staining of IL6 in the pancreas of RIP-IL6 Tg mice. Green: IL6; Blue:
t least 200 islets from 4 mice. B, C: Percentage of hyperglycemic mice in male (left) and
. Statistical signiﬁcance was determined by log-rank (ManteleCox) test. ***P < 0.001. D:
nic mice. Data are cumulated from two independent experiments are shown (n ¼ 5e7).
Fig. 2. CD11bþ cells, but not T cells, inﬁltrate the pancreas in RIP-NPþ/IL6þ double Tg mice. Representative cryosections of pancreata from 5-week old mice, stained for CD11b, CD4,
or CD8 (red-brown) and insulin (blue). Islets shown are representative for the predominant inﬁltration type (40e130 islets per group, 3e6 mice per group). B, C: mRNA expression
of inducible nitric oxide synthase (Inos; left), arginase-1 (Arg1, middle) and the ratio of Inos/Arg1 mRNA expression (right) in pancreases of RIP-NP/IL6 (B; n ¼ 5e6) and RIP-GP/IL6
(C; n ¼ 5e7) transgenic mice, analyzed by RT-qPCR and normalized to GAPDH using the DDCt method. Data cumulated from two independent experiments are shown. Lines
represent means.
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the expression of these genes, arguing against a shift toward
proinﬂammatory M1 macrophages in the pancreas of RIP-NP/IL6
mice (Fig. 2B). We obtained similar results in the RIP-GP/IL6
strain (Fig. 2C).
3.3. Deﬁcient GLUT-2 expression in RIP-NPþ/IL6þ and RIP-GPþ/IL6þ
double Tg mice
The absence of immune inﬁltrate suggests that the hypergly-
cemia in RIP-NPþ/IL6þ mice is not driven by autoimmunity, but
perhaps by perturbed insulin production and/or response. Immu-
nohistochemistry (data not shown) and immunoﬂuorescence mi-
croscopy revealed that beta-cells from RIP-NPþ/IL6þ mice still
contain insulin, but some islets showed an irregular insulin staining
pattern (Fig. 3A). This is apparent in all islets of these mice (Fig. 3A,
left column showing whole pancreas section overview). Gene
expression analysis nevertheless conﬁrms that Ins1 and Ins2 tran-
scripts are not present at lower amounts in the islets of RIP-NP/IL6
transgenic mice (data not shown). Restoring euglycemia using an
insulin pellet normalized this pattern, indicating that these micecan produce normal amounts of insulin and suggesting that the
irregular pattern of the insulin staining reﬂects the partial release of
insulin-containing secretory granules in hyperglycemic RIP-NPþ/
IL6þ mice. Besides insulin, also GLUT-2 (solute carrier family 2
member 2, SLC2A2) is required for glucose homeostasis and normal
function and development of the endocrine pancreas. Absence of
GLUT-2 prevents glucose-stimulated insulin secretion by beta-cells.
It is therefore interesting that we observed deﬁcient GLUT-2
expression in the pancreas of RIP-NPþ/IL6þ mice, regardless of
whether they were hyperglycemic or normoglycemic by insulin
pellet (Fig. 3A). Time-kinetic analysis showed that the disappear-
ance of GLUT-2 expression preceded the hyperglycemia and that
insulin expression in the islets remained intact before, during and
after hyperglycemia (Fig. 3B). To test the functional complications
of these observations, we performed an insulin tolerance test
showing a comparable outcome in RIP-NPþ/IL6þ double Tg mice
and single Tg or non-Tg littermates, indicating the response to in-
sulinwas not impaired (Fig. 3C). Of note, the response to insulinwas
not affected by the starting glycemia, as blood glycemia declined
proportionally equal in both normoglycemic and hyperglycemic
double Tg mice.
Fig. 3. Normal insulin sensitivity and impaired GLUT-2 production in RIP-NPþ/IL6þ double Tg mice. A: Expression of insulin (green) and GLUT-2 (red) revealed by immunoﬂuo-
rescence. Shown are whole pancreas cryosections from a representative mouse (1st and 3rd column) and pictures of individual islets (2nd and 4th column, representative for
approximately 120e180 islets from 2 to 3 mice per group). Data were conﬁrmed by IHC (data not shown). B: Time-kinetic analysis of insulin (green) and GLUT-2 (red) expression by
immunoﬂuorescence of pancreatic islets in female RIP-NPþ/IL6þ double Tg mice before, at or after diabetes onset. Dotted line delineates boundary of pancreatic islet. C: Insulin
tolerance test. Displayed is the blood glycemia normalized to the fasting glycemia in RIP-LCMV-NP/IL6 single and double Tg mice, as indicated.
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the production of inﬂammatory factors (e.g., prostaglandins) that in
turn inﬂuence the expression of insulin or Glut2 in RIP-IL6 Tg mice.
Because cyclooxygenase-2 (COX-2), an enzyme encoded by the
Prostaglandin-endoperoxide synthase 2 (Ptgs2) gene and is
responsible for the synthesis of prostaglandin H2 (PGH2) [23], is a
very important source of prostaglandins, we measured the mRNA
expression levels of COX-2 in the pancreas of RIP-NP/IL6 and RIP-
GP/IL6 mice. We could not ﬁnd statistically signiﬁcant differencesFig. 4. Normal glucose sensitivity, but impaired GLUT-2 expression in RIP-GPþ/IL6þ mice.
revealed by immunoﬂuorescence. Shown are pictures of individual islets of male or female m
group). Dotted line delineates boundary of pancreatic islet. N/A: Not available because RIP
tolerance test in RIP-GP/IL6 Tg mice. Shown are the mean  SEM of blood glycemia normain RIP/IL6þ Tg mice compared to RIP/IL6 counterparts (data not
shown). If anything, we observed a non-signiﬁcant trend for lower
COX-2 expression in RIP-NP þ IL6þ double Tg mice, ruling out an
important role played by this particular mediators in the pheno-
types we had observed.
The RIP-GP/IL6 line showed a phenotypic pattern that was
largely similar to the RIP-NP/IL6 line, namely pancreatic beta-cells
from RIP-GPþ/IL6þ double Tg mice also expressed insulin (Fig. 4A)
and gene expression analysis conﬁrms that Ins1 and Ins2 transcriptsA: Expression of insulin (columns 1 and 2, green) and GLUT-2 (columns 3 and 4, red)
ice as indicated (representative for approximately 120e180 islets from 2 to 3 mice per
-GPþ/IL6þ double Tg female mice do not become diabetic spontaneously. B: Glucose
lized to the fasting glycemia, per group as indicated.
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genic mice (data not shown). However, similar to our observations
in the RIP-NPþ/IL6þ mice, GLUT-2 expression was not detectable
(Fig. 4A). To test the functional complications of these observations,
we performed a glucose tolerance test. The blood glucose concen-
tration after the glucose injection followed a comparable curve in
RIP-GPþ/IL6þ double Tg mice and single Tg or non-Tg littermates,
indicating the RIP-GPþ/IL6þ double Tg mice were capable of con-
trolling a glucose bolus (Fig. 4B).
3.4. Beta-cell speciﬁc production of IL6 accelerates virus-induced
diabetes
Beta-cell speciﬁc production of IL6 alone does not induce dia-
betes [17], nor precipitates diabetes by LCMV virus on a diabetes
resistant background (Fig. 1). We examined whether IL6 increased
diabetogenic responses in the virus-induced model of autoimmune
diabetes [21,24,25]. Inoculation of RIP-LCMV-GPþ/IL6 mice
induced diabetes starting at day 10, and reaching 100% disease
penetrance by day 12 (Fig. 5A). Strikingly, beta-cell speciﬁc co-
expression of IL6 and GP signiﬁcantly accelerated diabetes onset
in the RIP-GPþ/IL6þ mice, starting as early as day 6 and reaching
100% disease penetrance by day 7 (Fig. 5A).
Immunohistochemistry analysis revealed more CD4þ and CD8þ
cells around and/or in the pancreatic islets and a strong inﬂux of
CD11bþ and CD11cþ cells in LCMV-inoculated GPþ/IL6þ versus GPþ/
IL6mice (Fig. 5B). This suggests that IL6 creates a proinﬂammatory
milieu supporting migration of immune cells and diabetogenicity.
Of note, without LCMV inoculation, GPþ/IL6þ or GPþ/IL6 did not
show inﬁltration of T cells (data not shown), similar to NPþ/IL6þ or
NPþ/IL6 without LCMV inoculation (Fig. 2).
IL6 did not increase autoantigen-speciﬁc CD8þ T cells in spleen
or pancreatic lymph nodes, as determined by pentamer stainingFig. 5. Beta-cell speciﬁc production of IL6 accelerates virus-induced diabetes. RIP-LCMV-GP
diabetes. A: Blood glycemia was monitored and percentage of hyperglycemic mice was pl
inﬁltration of CD4þ, CD8þ, CD11bþ and CD11cþ cells on day 7, revealed by immunohistochem
CeF: On day 7, spleen (top) and pancreatic lymph nodes (bottom) were harvested to measur
with GP33-41 peptide in the presence of Brefeldin A (D), or via IFN-g production by GP33
Foxp3þCD25þ in the live CD4 gate). Each dot represents one mouse. *P < 0.05 by two-taile(Fig. 5C), but a higher fraction of CD8þ T cells produced IFN-g
(Fig. 5D) or both TNF-a and IFN-g (data not shown) upon ex vivo
restimulation with GP33-41 peptide. This was because more of the
GP33-41/H-2Db-pentamerþ CD8þ T cells actually produced IFN-g
when restimulated ex vivo (Fig. 5E). We could not detect IL-17
production by T cells from RIP-LCMV-GPþ/IL6þ mice (data not
shown) [26], despite IL6 being an important driver for IL-17 pro-
duction [27]. On the other hand, we detected less CD4þ T cells with
a CD4þCD25þFoxp3þ Treg phenotype in the spleen and pancreatic
lymph node (Fig. 5F).
Thus, beta-cell speciﬁc IL6 expression increased autoantigen-
speciﬁc CD8þ T cell responses, while reducing the regulatory T
cell fraction.
3.5. Inoculation with Coxsackie virus B (CVB) or LCMV does not
cause diabetes RIP-IL6 mice
Viral infections, especially with human enterovirus (HEV), have
received much attention as potential environmental trigger of hu-
man T1D [4]. CVB has been shown to bear both enhancing and
protective capacity in the NOD mouse model of T1D, depending on
the context. CVB4 promotes diabetes in NOD mice [28], though
possibly depending on the time point at which infection occurs
[29]. CVB3 effectively suppresses diabetes incidence when inocu-
lated into healthy young NOD mice [30,31], but can rapidly trigger
diabetes in older, prediabetic NOD mice [32]. LCMV strain Arm-
strong is used as a means to induce diabetes in mice that trans-
genically express LCMV antigens in their beta-cells [24,25,33], but
otherwise LCMV infection efﬁciently prevents diabetes in NOD
mice [34,35]. We hypothesized that the local production of IL6
creates a proinﬂammatory milieu in the pancreas that sufﬁces to
confer diabetogenicity on infection with a pancreatropic virus. We
inoculated RIP-IL6 Tg mice with CVB3, a pancreatropic enterovirusþ/IL6þ mice or RIP-LCMV-GPþ/IL6 littermates were inoculated with LCMV to induce
otted. n ¼ 4e6 per group. **P ¼ 0.0013 by Log-rank (ManteleCox) test. B: Pancreatic
istry (blue: insulin, red: cell subset marker). Shown are pictures of representative islets.
e autoantigen-speciﬁc CD8þ T cells by pentamer staining (C), by ICCS upon stimulation
-41/Db pentamer positive CD8 T cells (E), as well as regulatory T cells (F; shown as %
d ManneWhitney test.
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infection that is nonpersisting but leads to immune-mediated
myocarditis, or with LCMV Armstrong, an arenavirus that causes
a systemic, acute infection that is asymptomatic and also non-
persisting. For CVB3 infection we used either the well-
characterized, poorly pathogenic CVB3 strain CVB3/GA as a slow-
replicator versus the fast-replicating CVB3/28 [30]. Infection with
any of these three viruses did not increase the blood glycemia
(Fig. 6A) and did not cause insulitis in the RIP-IL6 Tg mice (Fig. 6B).
This suggests that IL6-induced local inﬂammation is insufﬁcient to
allow viral infections to breach tolerogenic mechanisms.
4. Discussion
Studies looking into the role of IL6 in the pathogeneses under-
lying obesity, insulin resistance, beta-cell destruction, type 1 dia-
betes, and type 2 diabetes suggest both protective and pathogenic
actions of IL6 in diabetes [6]. We have shown here that production
of IL6 and antigen by b-cells can cause spontaneous hyperglycemia
and interferes with GLUT-2 expression. In the virus-induced mouse
model of autoimmune diabetes, IL6 expression accelerates diabetes
that is associated with increasing autoantigen-speciﬁc CD8 T cell
responses.
IL-6 is secreted by antigen-presenting cells in response to
external stimuli such as TNF-a, IL-1b but also bacterial and fungal
components. IL-6 is antagonistic for regulatory T cells andFig. 6. Infection with CVB3 or LCMV does not cause diabetes in Tg mice IL6 production
in the beta-cells. RIP-IL6 Tg mice were infected with Coxsackie Virus B3/28 (fast rep-
licator, 5  105 TCID50 i.p.), Coxsackie Virus B3/GA (slower replicator, 5  106 TCID50
i.p.) or LCMV Armstrong 53b (106 pfu i.p.). A: Average of blood glucose concentration,
and B: H&E staining of cryosections of pancreas, harvested at week 6 after inoculation
(3 mice per group).important for Th17 differentiation [37]. IL-6 is also sufﬁcient and
necessary for CD4þ T cells to induce production of IL-21 [38], a
cytokine critically required for autoimmune diabetes in NOD mice
[39,40]. Given such immunoregulatory actions of IL6, we wanted to
study the inﬂuence of local production of IL6 during virus-induced
diabetes using the RIPeLCMV system, a mouse model in which
diabetes is initiated by viral infection [21,24,25]. In LCMV-
inoculated RIP-LCMV-GP/IL6 line, we found that IL6 increased the
pancreatic inﬁltration by several immune cells, including T cells,
macrophages, dendritic cells and B cells (data not shown), thus
causing accelerated diabetes onset. This was associated with
increased LCMV-GP-speciﬁc effector CD8þ T cell responses and
reduced regulatory T cell fractions in the periphery, in line with a
proinﬂammatory role for IL6.
On the other hand however, local expression of IL6 is insufﬁcient
to confer diabetogenicity on viruses that can infect pancreatic beta-
cells. We tested LCMV as well as a slow and a fast-replicating CVB3.
Our data suggest that the viruses that could be involved in type 1
diabetes etiology still need a diabetes-prone genetic background
and that local IL6 expression is insufﬁcient to overcome these
diabetes-resistance mechanisms. Conversely, a number of viruses
that paradoxically induce strong inﬂammation and immune activ-
ity locally in the pancreas (while sparing b cells) during the pre-
diabetic phase are known to prevent T1D in NODmice [41]. Indeed,
infection of prediabetic NODmice with Coxsackie virus B3 or LCMV
delayed diabetes onset and reduced disease incidence [31]. We do
not yet know whether beta-cell speciﬁc IL6 expression can negate
such protection by viruses.
Surprisingly, the RIP-NPþ/IL6þ double Tg mice became hyper-
glycemic spontaneously, but the underlying mechanisms
remain elusive. The absence of pancreatic inﬁltration by T cells
suggested that the hyperglycemia is not associated with T cell
autoimmunity. On the other hand, our data tend to indicate that the
signiﬁcant increase in CD11b-positive cells in the pancreas might
be enough to cause impaired expression of Glut2, but that this goes
without an obvious shift to the proinﬂammatory M1-phenotype.
Further support that the reduction in GLUT-2 is not the result of
proinﬂammatory factors comes from the lack of increased expres-
sion in IL-6 Tg mice of COX-2 (data not shown), an enzyme that is
unexpressed under normal conditions in most cells, but becomes
upregulated only in cells where prostaglandins are upregulated, i.e.
during inﬂammation. Further studies are needed to assess the exact
nature and contribution of the inﬁltrating CD11bþ cells. Possibly,
the hyperglycemia could thus simply be the consequence of
disturbed glucose homeostasis, or insulin resistance, as can occur in
type 2 diabetes. Indeed, IL6 induces insulin resistance in cell culture
systems [42,43], underscoring its role in the development of dia-
betes in man. Nevertheless, both insulin levels in the pancreatic
beta-cells and response to insulin and glucose seemed to be normal
in the RIP-LCMV/IL6 double Tg mice. Interestingly, pancreatic beta-
cells of double Tg mice did not express detectable levels of GLUT-2,
a transmembrane protein that is normally highly expressed in
pancreatic beta-cells and is important in the up-take and meta-
bolism of glucose at the cellular level [44,45]. In streptozotocin-
treated rats, a decrease in the level of GLUT-2 correlated with the
diabetic state and with the glucose unresponsiveness of their islet
beta-cells [46]. However, it is puzzling why the RIP-GPþ/IL6þ
double transgenic mice are normoglycemic under steady state and
respond normal to GTT, yet have reduced expression of GLUT-2 in
the pancreatic islets. It is possible that the reduction of Glut2
expression in the RIP-GP/IL6 line is either compensated by other
GLUTs, or is not sufﬁciently low to impair the glucose sensitivity.
While we do not rule out compensation by other GLUTs, we deem it
less likely, because Glut2 is expressed at a very high level in
pancreatic beta-cells (and in the basolateral membranes of
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other Gluts mainly have a different cellular or anatomical distri-
bution [44]. At the moment, we therefore speculate that the
remaining expression of Glut2, although no longer detected using
standard immunoﬂuorescence microscopy, sufﬁces to maintain
normoglycemia in the RIP-GP/IL6 line. This is based on the uniquely
high Km of Glut2 for glucose (w17 mM) [47], which ensures fast
equilibration of glucose between the extracellular space and the
cell cytosol at all physiological or diabetes-associated glycemic
levels. This process is so efﬁcient that the rate of glucose meta-
bolism in the beta-cells is controlled at the glucose phosphoryla-
tion step and thus modulation of Glut2 surface expression usually
does not regulate metabolism except if its reduction is sufﬁcient to
limit glucose access to the hexokinases, as can happen in diabetic
conditions in beta-cells, or as can be seen in Glut2 gene-knockouts
were absence of Glut2 prevents glucose-stimulated insulin secre-
tion by beta-cells (and the regulation of glucose-sensitive gene
expression in hepatocytes). Because complete absence of GLUT-2
prevents glucose-stimulated insulin secretion by beta-cells, it is
possible that the lack of GLUT-2 in the RIP-NP/IL6 line impedes
rapid equilibration between the beta-cell cytosol and the extra-
cellular thereby impairing adequate release of insulin, resulting in a
hyperglycemic organismwith beta-cells still ‘full’ of insulin. Further
studies should unravel these puzzling observations.
The RIP-LCMV-GP strain does not express the GP in the thymus,
whereas the RIP-LCMV-NP strain expresses the NP in the thymus
and deletes the majority of the autoreactive T cells. Nevertheless, in
both cases, naive autoreactive CD8þ CTL are present in the pe-
riphery [48] and it is therefore unclear how, once crossed with RIP-
IL6 mice, spontaneous hyperglycemia occurs in one line and less in
the other. The very different pattern of diabetes development dis-
played by RIP-GP and RIP-NP mice when crossed with RIP-IL6 mice
was not the consequence of differences in the expression level of
IL6 in the pancreas of RIP-NPþ/IL6þ and RIP-GPþ/IL6þ mice. We
thus reasoned that the localization patterns of the NP or GP protein
can explain the different phenotypes. Based on work by the Buch-
meier lab [49], we conclude that the LCMV-GP is detectable in the
cytoplasm and on the surface of LCMV-infected cells. Work by
Zeller et al. [50] showed that most of the NP protein remains
intracellular, although a small part/epitope does appear on the
extracellular side. NP does not have a classical signal sequence (to
target it to the plasma membrane) e it has 8 hydrophobic regions
with a long enough sequence to be transmembrane. In the context
of infection it deﬁnitely makes it to the plasma membrane e and is
transmembrane e but we do not know if it requires accessory
proteins (viral GP) to localize effectively or not. It is possible,
although speculative, that the lack of a speciﬁc signal peptide
causes the NP protein to remain inside the cell in the transgenic
non-infected setting. However, not much is known about the sub-
cellular localization of NP and GP in the transgenic non-infected
setting. One of the few things we know, comes from one of our
earlier publications, in which we have shown reactivity to an anti-
LCMV serum in pancreatic sections of RIP-LCMV-GP strains, and
that expression level of GP in beta-cells corresponded to the degree
of diabetes pathogenesis [51]. However, the staining did not
address the localization of the GP in this transgenic setting. We do
know that MHC:peptide complexes must be on the surface of beta-
cells in the transgenic non-infected setting, because when LCMV-
speciﬁc cytotoxic T lymphocyte (CTL) clones were adoptively
transferred into RIP-LCMV-GP or RIP-LCMV-NPmice, theymigrated
speciﬁcally to the islets of Langerhans [24,25]. That said, a differ-
ence in surface expression of MHC:peptide complexes is unlikely to
explain the difference between the RIP-GP/IL and the RIP-NP/IL6
lines, given the absence of CD4þ or CD8þ T cell inﬁltration in RIP-
NPþ/IL6þ double transgenic diabetic mice.Contrary to surface-bound GP expression, simultaneous
expression of predominantly intracellular NP together with IL6may
lead to ER stress resulting in increased beta-cell death and antigen
release, thereby fueling the autoimmune response without the
need for prior LCMV infection. To address this, we determined the
expression of molecules upregulated during the course of the
unfolded protein response (UPR), namely C/EBP homologous Pro-
tein (CHOP) and spliced Xbox binding protein-1 (sXBP-1) (19; 28).
However, experiments on samples from RIP-GP/IL6 transgenic mice
revealed no signiﬁcant differences in expression of CHOP or sXBP-1
between single, double or non-transgenic littermates (data not
shown). Likewise, comparing RIP-NPþ/IL6þ versus RIP-GPþ/IL6þ
double transgenic mice revealed no differences in expression of
the tested ER-stress-related molecules (data not shown). Thus, the
mechanisms underlying the different clinical outcomes in RIP-NPþ/
IL6þ and RIP-GPþ/IL6þ mice still warrant further investigation.
IL6 plays a crucial role in the pathogenesis of many chronic in-
ﬂammatory and autoimmune diseases ranging from rheumatoid
arthritis and multiple sclerosis to uveoretinitis and asthma [52].
Our data conﬁrm and extend reports on an important pathogenic
role for IL6 in diabetes [17,18], consistent with the idea that IL6, like
TNF-a and Th1 cytokines, plays a key role in experimental IDDM
development [53] and increased levels of IL6 in patients with dia-
betes [9e12]. Continued interest in the development of anti-IL6
agents might also have a beneﬁcial outcome in type 1 diabetes
therapy.
5. Conclusions
We have attempted here to study the effect of b-cell speciﬁc IL-6
expression on spontaneous and virus-induced diabetes. We have
shown here that transgenic expression of IL-6 and LCMV viral
proteins in b-cells leads to disappearance of the glucose transporter
GLUT-2 in b-cells of both NPþ/IL6þ and GPþ/IL6þ Tg mice. However,
diabetes development is dramatically differently affected,
depending on whether the viral protein is a surface antigen
(glycoprotein, GP) or a nuclear antigen (nucleoprotein, NP). Mice
expressing IL-6 and nuclear protein (NP) in the b-cells became
spontaneously diabetic. In contrast, mice expressing IL-6 and sur-
face protein (GP) did not become spontaneously diabetic, but
showed accelerated LCMV-induced diabetes. Although further
research will be needed to unravel the mechanisms underlying
these observations, our data underscore the prodiabetic role for IL-
6, driving spontaneous and virus-induced diabetes, and highlight
the need for IL6 antagonists in type 1 diabetes therapy.
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